3D細胞培養：各種技術と世界の市場

世界の3D細胞培養の市場規模は、2023年の46億米ドルから、予測期間中に26.5％のCAGRで推移し、2028年には148億米ドルの規模に成長すると予測されています。

用途別では、研究用の市場が2023年の23億米ドルから、27.3%のCAGRで推移し、2028年には78億米ドルの規模に成長すると予測されています。また、バイオプロセス用の市場は2023年の22億米ドルから、25.7％のCAGRで推移し、2028年には70億米ドルに近い規模に成長すると予測されています。

当レポートでは、世界の3D細胞培養の市場を調査し、技術の発展の経緯、種類と概要、用途、R&D動向、市場規模の推移・予測、各種区分・地域別の詳細分析、競合情勢、主要企業のプロファイルなどをまとめています。

目次

第1章 イントロダクション

第2章 サマリー・ハイライト

• 市場の見通し
• 市場サマリー

第3章 市場概要

• 素晴らしい業界についての冒頭コメント
• 産業課題
• インビトロとインビボ
• 次元性
• 2Dおよび3D細胞培養の研究チェーン
• ベストプラクティス
• 標準化
• 規制
• FDAとゲノミクス
• 浸出物と抽出物
• 広範な問題
• 研究人材の不足
• 変わりゆく国際情勢
• イノベーションのペースと多様化
• 細胞培養の「その他」領域についてのコメント
• 場所を問わないオミクス
• 2020年は細胞培養業界にとって分岐点の年となるか？
• 予備的市場分析
• 細胞培養市場の成長率推計
• 大規模な培地消費のニーズの評価
• バイオ医薬品の将来の成長のモデル化
• 細胞培養市場の基本ケース
• 売上と成長の予測における課題
• 細胞培養培地の市場予測
• 細胞および遺伝子治療バイオプロセシングの分類
• バイオシミラーの培地消費の評価
• CDMO
• マイクロ流体工学
• バイオリアクター
• 内部細胞培養リソース
• バイオテクノロジーにおける所有の集中
• 3D細胞培養におけるイノベーションの特徴
• バイオプリンティングの戦略的ロードマップ

第4章 タイプ別市場

• 組織および細胞培養のはじまり
• 歴史と初期の応用
• 組織培養の発明
• 持続細胞株の開発
• 最初の細胞培養フラスコと厳密な技術
• Lindbergh：細胞培養装置のパイオニア
• 連続細胞株の確立
• 機器の主な発展
• 用語と概念
• 組織および細胞培養産業
• 組織培養と細胞培養の定義
• 細胞株
• 細胞培養システムのケアと増殖
• 培地、血清、試薬
• ゲルとスキャフォールド
• マイクロプレート/マイクロタイタープレート
• バイオ分析機器
• バイオ分析イメージング
• バイオプリンティング
• バイオリアクター
• その他の細胞培養装置
• 接着アプローチ
• 従来のローラーボトル
• その他のシステム
• IT：細胞培養研究市場向けのソフトウェアとサービス
• 細胞培養研究市場向けソフトウェア
• ソフトウェア関連のサポートサービス
• 細胞培養用のバイオプロセシング消耗品
• 大規模3D培養用マイクロキャリア
• 大規模3D培養用Sera
• 大規模3D培養用メディア
• 大規模3D培養用バイオリアクターバッグ
• その他
• バイオプロセス装置
• バイオプロセス用分析装置
• バイオプロセシング用自動化システム
• バイオプロセシング支援装置
• バイオ医薬品とワクチンの大規模製造の側面
• 懸濁タンパク質とモノクローナル抗体
• 付着細胞ベースの治療法とワクチン
• 体細胞、幹細胞、組織を作製するための小規模接着剤
• ワクチン
• 触媒としてのワクチン開発
• ヒト細胞株を使用して開発されたワクチン
• エクソソーム製造
• ウイルスベクター製造
• レンチウイルス製造
• プラスミド製造
• 細胞培養エンドユーザー
• 製薬/バイオ製薬
• 大学
• 政府
• CRO/CDMOS
• その他
• 細胞培養の用途
• 創薬
• 臨床開発
• 毒物学
• 基礎研究
• バイオプロセシング開発
• その他
• 地域市場
• 南北アメリカ
• 欧州
• アジア太平洋
• その他の地域

第5章 アッセイ・イメージング・分析

• アッセイ
• 間葉系幹細胞のアッセイ開発
• 外来性病原体のインビトロ試験
• アッセイおよびアッセイキット
• 細胞ベースアッセイ：概要と新しい開発
• 細胞ベースアッセイで使用される細胞
• 3D細胞ベースアッセイに関する注意事項
• 動態代謝アッセイ
• 細胞増殖
• 生存率と細胞毒性
• 細胞生存率と生存率の透過性アッセイ
• 細胞侵入
• 細胞のシグナル伝達とコミュニケーション
• 細胞増殖抑制性
• 細胞死アッセイ
• イメージング技術
• イメージングアッセイ
• スクリーニングの推進力としての蛍光
• 組織および細胞培養で使用される分析システム
• 「セロミクス」を理解する
• HCSによる3D細胞培養のサポート
• NGSディスカバリープール
• マルチプレックスアッセイ
• 予測毒性学
• ニューロセーフティ
• オミックスの侵略
• トランスクリプトミクス

第6章 規制・標準化

• バイオプリント製品の米国の規制状況
• 生物製剤規制に関する基本指針
• 再生医療指導
• 異種移植に関するガイダンス
• 再生医療に関するガイドライン：緊急承認
• バイオプリント製品の規制

第7章 癌の3Dモデル

• 疾患モデリング
• 癌
• 癌やその他の疾患を研究するためのモデルの主なクラス
• 細胞株
• スフェロイドとオルガノイド
• 遺伝子操作マウスモデル (GEMM)
• 患者由来腫瘍異種移植片 (PDX)
• 概要：細胞レベルの癌
• In Vivo (動物) 試験基準
• マウス・エンパイア
• ヒト化マウス
• 2D培養
• 3D要件
• 細胞数と生存率
• 移住と侵略
• アンメットニーズ：血管新生と免疫システム回避
• 癌研究における3Dモデルの利点
• 細胞の形態と増殖における優れた区別
• 遺伝子発現と細胞の挙動の向上
• 細胞の移動と浸潤のより優れたモデル
• 細胞の不均一性
• 3D培養の原動力としての乳癌
• 構造、極性、アポトーシス
• 3D培養の推進者としての黒色腫
• Spheroid構成への移行
• 癌研究における3Dシステム
• 多細胞腫瘍スフェロイド
• 多層細胞培養
• 3D設計スキャホールド
• 天然素材
• 合成材料
• ヒト癌モデルイニシアチブ (HCMI)
• 次世代ヒト癌モデル
• 薬物感受性と耐性
• シグナル伝達と感度の変化
• 薬剤耐性
• セルラーシグナリング
• インテグリンを介した細胞シグナル伝達
• 薬物スクリーニング
• アプローチとエンドポイント
• スフェロイドの用途
• 3D細胞遊走モデルによる転移
• 肺オンチップを介した転移
• 癌の代謝
• 未来の地平線
• 転移
• 共培養
• 血管新生
• 癌関連線維芽細胞
• 癌幹細胞
• 併用療法
• 生物製剤の開発
• 腫瘍の再発
• 患者由来細胞
• 患者由来腫瘍異種移植片 (PDX)
• PDXプラットフォームの進化

第8章 毒物学および医薬品安全性試験の情勢

• 肝臓
• 毒物の背景
• 皮膚への副作用テスト
• 新しい評価方法が3D細胞培養に与える影響
• 化粧品の毒性試験
• 更新された規制要件
• 化粧品および薬用化粧品の効能
• 化粧品の毒性試験の側面
• 皮膚の炎症
• 皮膚腐食
• 光毒性
• 皮膚感作性
• 目の炎症
• 急性全身毒性
• 急性毒性試験
• 急性毒性試験のための細胞毒性アッセイ
• 慢性および反復投与毒性
• 発癌性と遺伝毒性
• 概要
• In Vitroメソッド：背景と最近の開発
• 規制申請と医薬品開発申請
• 誤検知を減らすための取り組み
• スクリーニングにおける最近の革新
• 将来の課題：非遺伝毒性の発癌性物質
• 生殖および発生毒性
• 背景
• 生殖周期
• 発生および生殖毒性試験の種類
• 発生毒性スクリーニング用ゼブラフィッシュモデル
• ゼブラフィッシュと幹細胞の組み合わせ
• 生物医学のフロンティア：男性の精巣
• 内分泌かく乱物質のスクリーニング
• 背景
• 環境毒性学がIn Vitro法に与える影響
• ToxCastとTox 21の取り組み
• 今後の課題：甲状腺破壊
• BG1アッセイ
• トキシコキネティクスとADME
• インビトロ開発
• 代謝
• 低代謝回転化合物の薬物動態
• 器官型モデル
• 皮膚の3Dモデル
• 3D角膜システム
• 吸収バリアモデル
• 胃腸
• 肺
• 血液脳関門
• 3D組織バリアと細胞外マトリックスの実際のアーキテクチャ
• 肝臓毒性
• 肝臓の特異性と複雑性
• 3Dイノベーションの鍵となる肝臓
• インビトロ肝臓用途
• In Vivo肝機能と構造
• 肝臓の代謝
• インビトロ肝臓モデル
• 肝細胞とマクロファージの共培養
• 3D肝臓モデル
• バイオプリントされた肝臓組織
• 検出された肝圏の構造と機能
• 理想的な基準
• 薬剤耐性
• トランスポーター研究
• 異型の細胞間接触の実現
• アンメットニーズと将来のイノベーションの原動力
• モルフォゲンシグナル伝達
• マルチドナー肝細胞
• 腎臓毒性への応用
• 今後の課題：幹細胞由来腎臓細胞
• バイオプリント腎臓組織
• 膵臓毒性学の応用
• 心血管毒性
• 商業化の道程
• 規制当局との協力
• 心血管創薬
• インピーダンスに基づく微小電極アレイ (MEA)
• バイオプリント磁気別大動脈輪アッセイの代用
• 血管拡張活性
• 3D人工心臓組織

第9章 地域別市場内訳

• 北米
• 米国
• カナダ
• 欧州
• ドイツ
• 英国
• アジア太平洋
• 中国
• 日本
• インド
• 韓国
• シンガポール
• その他の地域

第10章 幹細胞の情勢

• 幹細胞の歴史
• 幹細胞の主な研究分野
• 3D幹細胞培養システム
• プレートまたは培養皿
• スピナーフラスコと回転壁容器
• 灌流バイオリアクターおよびマイクロキャリアシステム
• 欠点
• マイクロ流体工学と幹細胞
• 幹細胞生物学の短いレビュー
• 胚発生
• 幹細胞の増殖、構造、形態
• 幹細胞の分化
• 幹細胞の分化と増殖
• 細胞外マトリックスと幹細胞
• 可溶性因子
• 幹細胞の製造
• 胚様体形成の制御
• 強制的な集合文化
• ハンギングドロップアプローチ
• 用途
• ハイスループットスクリーニング用の幹細胞マーカー
• 奇形腫と奇形腫アッセイ
• 富士フイルム (Cellular Dynamics Inc.)
• 幹細胞研究の画期的な進歩
• 神経科学の発見と開発のための幹細胞
• 例：アルツハイマー病の研究
• 背景：B-アミロイドカスケード仮説
• ヒトiPS細胞由来モデル
• 新しい3Dモデル
• 3Dのその他の利点
• 想定される用途
• その他の3D Neuro用途
• 心血管の発見のための幹細胞
• 再生医療開発のための幹細胞
• 背景：同種異系対自家
• マイクロRNA
• 人工多能性幹細胞 (IPS)

第11章 再生医療：臓器移植と代用皮膚

• 再生医療
• 臓器移植の必要性
• 再生医療への応用
• 再生医療への投資
• 皮膚代替品産業
• 組織培養同種移植片および自家移植片製品
• 再生医療における組織工学

第12章 企業プロファイル

• 3D BIOPRINTING SOLUTIONS
• 3D BIOTEK LLC
• 4D TECHNOLOGY CORP.
• ABCAM PLC
• AKRON BIOTECH
• AGILENT TECHNOLOGIES INC.
• ALPCO
• AMSBIO
• BECKMAN COULTER INC.
• BIOINSPIRED SOLUTIONS
• BIOTIME INC.
• BIOVISION INC.
• CELL APPLICATIONS INC.
• CELLINK
• CORNING INC.
• CYPROTEX
• CYTIVA
• CYTOO SA
• EMD MILLIPORE/MERCK KGAA
• EMULATE INC.
• ENVISIONTEC INC.
• EPITHELIX
• EUROFINS SAS
• GREINER BIO-ONE INTERNATIONAL GMBH
• HAMILTON ROBOTICS
• HUB ORGANOIDS
• HUREL CORP.
• INSPHERO
• INVITROCUE
• KIYATEC INC.
• LIFENET HEALTH
• LOREM VASCULAR/CYTORI THERAPEUTICS INC.
• MATTEK
• MIMETAS INC.
• ORGANOVO HOLDINGS INC.
• PERKINELMER INC.
• PLASTICELL LTD.
• PLURISTEM THERAPEUTICS INC.
• POIETIS
• PROMEGA CORP.
• SEAHORSE BIOSCIENCE
• STEMCELL TECHNOLOGIES
• STRATATECH CORP.
• SYNVIVO INC.
• TAP BIOSYSTEMS
• TECAN TRADING AG
• ZEN-BIO INC.

List of Tables

• Summary Table : Global Market for 3D Cell Culture, by Segment, Through 2028
• Table 1 : Dimensionality of Cell Culture
• Table 2 : WHO R&D Roadmap of Priority Infectious Diseases
• Table 3 : 3D Bioprinting Roadmap
• Table 4 : Selected Online Prices for Bioreactors
• Table 5 : Global Market for 3D Cell Culture, by Segment, Through 2028
• Table 6 : Tissue Types
• Table 7 : Cell Types Based on Developmental Origin
• Table 8 : Leading Cell Line Suppliers, April 2020
• Table 9 : Commonly Used Transformed Cells Lines
• Table 10 : Major Primary Cell Lines
• Table 11 : Leading Primary Cell Suppliers
• Table 12 : Main Types of Stem Cells
• Table 13 : Stem Cell Services
• Table 14 : Areas of Interest in 3D Spheroid Research
• Table 15 : Selected Nanoparticle Products Used in Life Science Research
• Table 16 : Results of Liver-Chip Drugs Halted in Previous Clinical Trials Based on Animal Studies
• Table 17 : Companies and Universities Involved in the Organ-on-a-Chip Industry
• Table 18 : Microfluidics Companies
• Table 19 : Selected Recent Patents Issued on Microfluidic Devices Related to Cell Culture Applications
• Table 20 : Selected Papers Published on Recent Microfluidic Advances in Cell Culture
• Table 21 : High-Content Screening Suppliers and Key Attributes
• Table 22 : Selected Patents Issued Related to Flow Cytometers
• Table 23 : Thermo Fisher Imaging Products
• Table 24 : Recent Bioprinting Company Deals and Strategic Partnerships
• Table 25 : Bioprinting Modalities
• Table 26 : Maintaining Cell Viability During Printing
• Table 27 : Bioprinting Instrument Industry
• Table 28 : Biomaterial Components
• Table 29 : Bioink Types
• Table 30 : Classes of Matrix Bioink Hydrogels
• Table 31 : Matrix Bioink Selection Criteria
• Table 32 : Selected Bioink Companies, 2020
• Table 33 : Projected Unit Sales of Research Bioreactors, <10 Liters, 2020
• Table 34 : Leading Bioreactor Suppliers, 2020
• Table 35 : Label-Free Technologies and Suppliers
• Table 36 : Developmental Issues Facing the Commercialization of Exosomes
• Table 37 : Companies Working on Exosome Products
• Table 38 : Global Market for Cell Culture, by End User, Through 2028
• Table 39 : Global Market for Cell Culture, by Application, Through 2028
• Table 40 : Global Market for Cell Culture, by Region, Through 2028
• Table 41 : Typical Assay Endpoints and Tests
• Table 42 : U.S. Patents on Assays Systems, 2019 and 2020
• Table 43 : Selected U.S. Patents on Assay Imaging, 2019 and 2020
• Table 44 : Recently Issued U.S. Patents on Cellomics, 2019
• Table 45 : Toxicology Issues That Need to Be Addressed for FDA-Regulated Products
• Table 46 : Overview of Federal Regulation of the Cell Culture Markets
• Table 47 : FDA List of Cell, Biologic and Tissue Products Regulated Under CBER and CDRH
• Table 48 : FDA "Talking Point" Recommendations for Regenerative Medicine Advanced Therapies (RMATs)
• Table 49 : U.S. Regulatory Considerations for Bioprinted Biologics
• Table 50 : Main Types of Models for Researching Cancer and Other Diseases
• Table 51 : Goals of Funding Opportunity Announcement RFA-CA-19-055
• Table 52 : Common 3D Assays
• Table 53 : Summary of the Benefits and Advantages of EV3D
• Table 54 : ECVAM List of Current Activities, 2020
• Table 55 : In Vitro Testing in Cosmetics, by Test Class
• Table 56 : Global Market for Cell Culture by Region, Through 2028
• Table 57 : North American Market for Cell Culture by Country, Through 2028
• Table 58 : European Market for Cell Culture by Country, Through 2028
• Table 59 : Asia-Pacific Market for Cell Culture by Country, Through 2028
• Table 60 : RoW Market for Cell Culture by Region, Through 2028
• Table 61 : Major and Minor Research Areas in Stem Cells
• Table 62 : Stem Cell Usage in Research
• Table 63 : Recent U.S. Patents Granted on Stem Cell Technologies
• Table 64 : Papers Published on Selected Stem Cell Research Trends
• Table 65 : Comparison of the Number of Citations in the Literature on Cell Culture versus Stem Cell Culture
• Table 66 : Number of Organ Transplants Performed in the United States, 2018 and 2019
• Table 67 : Total Global Financing of Regenerative Medicine
• Table 68 : Total Financing of Regenerative Medicine, by Therapeutic Area
• Table 69 : Leading Tissue Products and Suppliers
• Table 70 : Printed Tissue and Organs: Commercialization Timeframe
• Table 71 : Tissue/Organ Complexity
• Table 72 : 3D Bioprinting Solutions: Company Snapshot
• Table 73 : 3D Biotek LLC: Company Snapshot
• Table 74 : 4D Technology Corp.: Company Snapshot
• Table 75 : Abcam Plc: Company Snapshot
• Table 76 : Abcam PLC: Financial Performance, 2022
• Table 77 : Akron Biotech: Company Snapshot
• Table 78 : Agilent Technologies: Company Snapshot
• Table 79 : Agilent Technologies Inc.: Financial Performance, 2022
• Table 80 : Alpco: Company Snapshot
• Table 81 : Amsbio: Company Snapshot
• Table 82 : Beckman Coulter: Company Snapshot
• Table 83 : Bioinspired Solutions: Company Snapshot
• Table 84 : BioTime Inc.: Company Snapshot
• Table 85 : Biovision Inc.: Company Snapshot
• Table 86 : Cell Applications Inc.: Company Snapshot
• Table 87 : Cellink: Company Snapshot
• Table 88 : Corning Inc.: Company Snapshot
• Table 89 : Corning Inc.: Financial Performance, 2022
• Table 90 : Cyprotex: Company Snapshot
• Table 91 : Cytiva: Company Snapshot
• Table 92 : Cytoo SA: Company Snapshot
• Table 93 : Merck KGAA: Company Snapshot
• Table 94 : Merck KGAA: Financial Performance, 2022
• Table 95 : Emulate Inc.: Company Snapshot
• Table 96 : EnvisionTec Inc.: Company Snapshot
• Table 97 : Epithelix: Company Snapshot
• Table 98 : Greiner Bio-One International GmbH: Company Snapshot
• Table 99 : Hamilton Robotics: Company Snapshot
• Table 100 : HUB Organoids: Company Snapshot
• Table 101 : Hurel Corp.: Company Snapshot
• Table 102 : Insphero: Company Snapshot
• Table 103 : Invitrocue: Company Snapshot
• Table 104 : Kiyatec Inc.: Company Snapshot
• Table 105 : LifeNet Health: Company Snapshot
• Table 106 : Cytori Therapeutics Inc.: Company Snapshot
• Table 107 : Mattek: Company Snapshot
• Table 108 : Mimetas Inc.: Company Snapshot
• Table 109 : Organovo Holdings Inc.: Company Snapshot
• Table 110 : PerkinElmer Inc.: Company Snapshot
• Table 111 : Plasticell Ltd.: Company Snapshot
• Table 112 : Pluristem Therapeutics Inc.: Company Snapshot
• Table 113 : Poietis: Company Snapshot
• Table 114 : Promega Corp.: Company Snapshot
• Table 115 : SeaHorse Bioscience: Company Snapshot
• Table 116 : Stemcell Technologies: Company Snapshot
• Table 117 : Stratatech Corp.: Company Snapshot
• Table 118 : Synvivo Inc.: Company Snapshot
• Table 119 : Tap Biosystems: Company Snapshot
• Table 120 : Tecan Trading AG: Company Snapshot
• Table 121 : Zen-Bio Inc.: Company Snapshot

List of Figures

• Summary Figure : Global Market for 3D Cell Culture, by Segment, 2020-2028
• Figure 1 : Research Chain for Cell Culture
• Figure 2 : A Model for The Evolution of FDA Regulation
• Figure 3 : 3D Cell Cultures: Market Dynamics
• Figure 4 : An Innovation Matrix
• Figure 5 : Bioprinting Strategic Roadmap
• Figure 6 : Global Market Shares of 3D Cell Culture, by Segment, 2022
• Figure 7 : Gastrointestinal Organotype Cultures
• Figure 8 : iCELLis Nanoreactor: Example of Commercial 2D Cell Culture Systems
• Figure 9 : Prototype of 3D Model Lung-on-a-Chip from Wake Forest
• Figure 10 : Recent Photo of the HepaChip
• Figure 11 : Recent Photo of the HepaChip-MWP
• Figure 12 : University of Toronto Handheld Bioprinting Device
• Figure 13 : Collaborative Experiment Conducted by American, Russian and Israeli Scientists
• Figure 14 : Smart Marbles Concept for Quantifying Process Heterogeneity
• Figure 15 : Porcine Intestinal Organoids
• Figure 16 : Diagram of the Components of a Predictive Toxicology System
• Figure 17 : Gleason's Pattern
• Figure 18 : Diagram of PDXs, Cell Lines and Organoid/Spheroid Xenografts
• Figure 19 : Cell Heterogeneity and Its Function
• Figure 20 : Global Market for Cell Culture by Region, 2020-2028
• Figure 21 : North American Market for Cell Culture by Country, 2020-2028
• Figure 22 : European Market for Cell Culture by Country, 2020-2028
• Figure 23 : Asia-Pacific Market for Cell Culture by Country, 2020-2028
• Figure 24 : ROW Market for Cell Culture by Region, 2020-2028
• Figure 25 : Electron Micrograph of Porous Microcarrier for Stem Cell Production
• Figure 26 : Photograph of Apligraf
• Figure 27 : Abcam PLC: Financial Performance, 2021 and 2022
• Figure 28 : Abcam PLC: Revenue Shares, by Country/Region, 2022
• Figure 29 : Agilent Technologies Inc.: Financial Performance, 2021 and 2022
• Figure 30 : Agilent Technologies Inc.: Revenue Shares, by Business Unit, 2022
• Figure 31 : Agilent Technologies Inc.: Revenue Shares, by Country/Region, 2022
• Figure 32 : Corning Inc.: Revenue Shares, by Business Unit, FY 2022
• Figure 33 : Corning Inc.: Revenue Shares, by Region, FY 2022
• Figure 34 : Merck KGAA: Revenue Shares, by Business Unit, FY 2022
• Figure 35 : Merck KGAA: Revenue Shares, by Region, FY 2022

Highlights:

The global market for 3D cell culture is estimated to increase from $4.6 billion in 2023 to reach $14.8 billion by 2028, at a compound annual growth rate (CAGR) of 26.5% from 2023 through 2028.

The global market for 3D cell culture for research segment is estimated to increase from $2.3 billion in 2023 to reach $7.8 billion by 2028, at a CAGR of 27.3% from 2023 through 2028.

The global market for 3D cell culture for bioprocessing segment is estimated to increase from $2.2 billion in 2023 to reach nearly $7.0 billion by 2028, at a CAGR of 25.7% from 2023 through 2028.

Report Scope:

This report aims to provide a comprehensive study of the global 3D cell culture technologies market. It provides a detailed description of the different types of healthcare interoperability solutions and their current and historical market revenues.

The scope of the report encompasses the major types of 3D cell culture which are being used by industry, academic researchers, government labs, and independent research groups. This includes the main inputs such as cell lines, media, sera, reagents, software, and instrumentation. It analyzes the current market status, examines future market drivers and presents forecasts of growth over the next five years.

The market structure has been reorganized for this edition. Also, more research was done on base case data for different product areas. The greater emphasis is on the different products used for 3D cell culture, but the report also investigates the market in terms of types of applications, end users and geographic regions.

Report Includes:

• 17 data tables and 105 additional tables
• An overview of the global market landscape related to the 3D cell cultures technologies
• In-depth analysis of global market trends, featuring historical revenue data for 2020-2022, estimated figures for 2023, as well as forecasts for 2028. This analysis includes projections of Compound Annual Growth Rates (CAGRs) spanning through 2028
• Evaluation of the current market size and revenue growth prospects specific to 3D cell cultures technologies, accompanied by a comprehensive market share analysis categorized by type, end user, and geographical region
• Information on analytical systems used in tissue and cell culture, cellomics, and human cancer model initiative (HCMI)
• Details about assay development for mesenchymal stem cells, In Vitro testing of adventitious agents and description of assays and assay kits
• A look at the main classes of models for researching cancer and other diseases, benefits of 3D models to cancer research and description of 3D engineered scaffolds
• Analysis of the market's dynamics, specifically growth drivers, restraints, and opportunities and discussion on the impact of COVID-19 on the world of cell culture
• Insights into U.S. regulatory status of bioprinted products; basic guidance for the regulation of biologics, regenerative medicine and xenotransplants
• Relevant patent analysis, including recent activity and a list of key patents
• Detailed profiles of leading market participants, providing a descriptive overview of their respective businesses, including Abcam PLC, Agilent Technologies Inc., Corning Inc., Merck KGAA, Beckman Coulter, and Synvivo Inc.

Table of Contents

Chapter 1 Introduction

• Study Goals and Objectives
• Reasons for Doing the Study
• Scope of Report
• What's New in This Report?
• Methodology and Information Sources
• Geographic Breakdown
• Segment Breakdown

Chapter 2 Summary and Highlights

• Market Outlook
• Market Summary

Chapter 3 Market Overview

• An Opening Comment on an Amazing Industry
• Industry Issues
• In Vitro versus In Vivo
• Dimensionality
• The Research Chain for 2D and 3D Cell Culture
• Best Practices
• Standardization
• Regulation
• Genomics Forcing the Hand of the FDA
• Leachables and Extractables
• Broad Issues
• Research Talent Shortages
• The Shifting International Picture
• Pace and Diversification of Innovation
• A Comment on the "Other" Areas of Cell Culture
• Omics Everywhere
• Is 2020 a Watershed Year for the Cell Culture Industry?
• Preliminary Market Analysis
• Cell Culture Market Growth Rate Estimates
• Assessing Large-Scale Media Consumption Needs
• Modeling Future Growth in Biopharmaceuticals
• Base Case for the Cell Culture Market
• Challenges in Projecting Sales and Growth
• Cell Culture Media Market Estimates
• Cell and Gene Therapy Bioprocessing Segment
• Evaluating Media Consumption for Biosimilars
• What About CDMOs?
• Microfluidics
• Bioreactors
• Internal Cell Culture Resources
• Is There Too Much Concentration of Ownership in Biotechnology?
• Characterizing Innovation in 3D Cell Culture
• Bioprinting Strategic Roadmap

Chapter 4 Market, by Type

• Where Did Tissue and Cell Culture Start?
• History and Early Applications
• Invention of Tissue Culture
• Development of Sustained Cell Lines
• First Cell Culture Flask and Rigorous Techniques
• Lindbergh: The Cell Culture Equipment Pioneer
• Establishing Continuous Cell Lines
• Key Developments in Equipment
• Terminology and Concepts
• Tissue and Cell Culture Industry
• Tissue Culture and Cell Culture Definitions
• Cell Lines
• Care and Growth of Cell Culture Systems
• Media, Sera, and Reagents
• Gels and Scaffolds
• Microplates/Microtiter Plates
• Bioanalytical Instruments
• Bioanalytical Imaging
• Bioprinting
• Bioreactors
• Other Equipment for Cell Culture
• Adherent Approaches
• Traditional Roller Bottles
• Other Systems
• Information Technology: Software and Services for the Cell Culture Research Market
• Software for the Research Market in Cell Culture
• Software-Related Support Services
• Bioprocessing Consumables for Cell Culture
• Microcarriers for Large-Scale 3D Culture
• Sera for Large-Scale 3D Culture
• Media for Large-Scale 3D Culture
• Bioreactor Bags for Large-Scale 3D Culture
• Other
• Bioprocessing Equipment
• Analytical Equipment for Bioprocessing
• Automation Systems for Bioprocessing
• Support Equipment for Bioprocessing
• Aspects of Large-Scale Manufacturing of Biopharmaceuticals and Vaccines
• Suspension Proteins and Monoclonal Antibodies
• Adherent-Cell-Based Therapies and Vaccines
• Small-Scale Adherent to Make Somatic Cells, Stem Cells and Tissues
• Vaccines
• Vaccine Development as a Catalyst
• Vaccines Developed Using Human Cell Strains
• Exosome Manufacturing
• Viral Vector Manufacturing
• Lentivirus Manufacturing
• Plasmid Manufacturing
• Cell Culture End Users
• Pharma/Biopharma
• Universities
• Government
• CROs/CDMOS
• Other
• Cell Culture Applications
• Drug Discovery
• Clinical Development
• Toxicology
• Basic Research
• Bioprocessing Development
• Other
• Regional Markets
• The Americas
• Europe
• Asia-Pacific
• Rest of the World

Chapter 5 Assays, Imaging and Analysis

• Assays
• Assay Development for Mesenchymal Stem Cells
• In Vitro Testing of Adventitious Agents
• Assays and Assay Kits
• Cell-Based Assays: Overview and Newer Developments
• Cells Used in Cell-Based Assays
• Notes on 3D Cell-Based Assays
• Kinetic Metabolism Assays
• Cell Proliferation
• Viability and Cytotoxicity
• Permeability Assays for Cell Viability and Survival
• Cell Invasion
• Cell Signaling and Communication
• Cytostatic
• Cell Death Assays
• Imaging Technology
• Imaging Assays
• Fluorescence as a Driver of Screening
• Analytical Systems Used in Tissue and Cell Culture
• Understanding "Cellomics"
• HCS Support of 3D Cell Culture
• NGS Discovery Pools
• Multiplex Assays
• Predictive Toxicology
• Neuro Safety
• The Omics Invasion
• Transcriptomics

Chapter 6 Regulation and Standardization

• U.S. Regulatory Status of Bioprinted Products
• Basic Guidance for the Regulation of Biologics
• Guidance for Regenerative Medicine
• Guidance for Xenotransplants
• Guidance for Regenerative Medicine: Emergency Approval
• Regulating Bioprinted Products

Chapter 7 3D Models for Cancer

• Disease Modeling
• Cancer
• Main Classes of Models for Researching Cancer and Other Diseases
• Cell Lines
• Spheroids and Organoids
• Genetically Engineered Mouse Model (GEMM)
• Patient-Derived Tumor Xenografts (PDXs)
• Overview: Cancer at the Cellular Level
• In Vivo (Animal) Testing Standard
• Empire of the Mouse
• Humanized Mice
• 2D Culture
• 3D Requirements
• Cell Number and Viability
• Migration and Invasion
• Unmet Needs: Angiogenesis and Immune System Evasion
• Benefits of 3D Models to Cancer Research
• Greater Distinction in Cell Morphology and Proliferation
• Greater Gene Expression and Cell Behavior
• Better Models of Cell Migration and Invasion
• Cell Heterogeneity
• Breast Cancer as a Driver of 3D Cultures
• Structure, Polarity and Apoptosis
• Melanoma as a Driver of 3D Cultures
• Moving to Spheroid Configurations
• 3D Systems in Cancer Research
• Multicellular Tumor Spheroids
• Multilayered Cell Cultures
• 3D Engineered Scaffolds
• Natural Materials
• Synthetic Materials
• Human Cancer Model Initiative (HCMI)
• Next-Generation Human Cancer Models
• Drug Sensitivity and Resistance
• Altered Signaling and Sensitivity
• Drug Resistance
• Cellular Signaling
• Cellular Signaling Mediated by Integrins
• Drug Screening
• Approaches and Endpoints
• Spheroid Applications
• Metastasis via 3D Cell Migration Model
• Metastasis via Lung-on-Chip
• Cancer Metabolism
• Future Horizons
• Metastases
• Co-culture
• Vascularization
• Cancer-Associated Fibroblasts
• Cancer Stem Cells
• Combination Therapies
• Biologics Development
• Tumor Recurrence
• Patient-Derived Cells
• Patient-Derived Tumor Xenografts (PDXs)
• Evolution of PDX Platforms

Chapter 8 Landscape for Toxicology and Drug Safety Testing

• Introduction
• Liver
• Toxicology Background
• Testing for Adverse Effects on the Skin
• New Assessment Methodologies Impact on 3D Cell Culture
• Toxicology Testing in Cosmetics
• Updated Regulatory Requirements
• Efficacy of Cosmetics and Cosmeceuticals
• Aspects of Cosmetic Toxicity Testing
• Skin Irritation
• Skin Corrosion
• Phototoxicity
• Skin Sensitization
• Eye Irritation
• Acute Systemic Toxicity
• Acute Toxicity Testing
• Cytotoxicity Assays for Acute Toxicity Testing
• Chronic and Repeated Dose Toxicity
• Carcinogenicity and Genotoxicity
• Overview
• In Vitro Methods: Background and Recent Developments
• Regulatory versus Drug Development Applications
• Efforts to Reduce False Positives
• Recent Innovations in Screening
• Future Challenge: Non-genotoxic Carcinogens
• Reproductive and Developmental Toxicity
• Background
• Following the Reproductive Cycle
• Development and Reproductive Tox Testing Types
• Zebrafish Model for Developmental Toxicity Screening
• Combination of Zebrafish and Stem Cells
• Biomedical Frontiers: Male Testis
• Endocrine Disruptor Screening
• Background
• Environmental Toxicology Impacts In Vitro Methods
• ToxCast and Tox 21 Initiatives
• Future Challenge: Thyroid Disruption
• BG1 Assay
• Toxicokinetics and ADME
• In Vitro Developments
• Metabolism
• Pharmacokinetics of Low-Turnover Compounds
• Organotypic Models
• 3D Models for Skin
• 3D Corneal System
• Absorption Barrier Models
• Gastrointestinal
• Lung
• Blood-Brain Barrier
• Real Architecture for 3D Tissue Barriers and Extracellular Matrix
• Liver Toxicity
• Uniqueness and Complexity of Liver
• Liver as a Key Driver for 3D Innovation
• In Vitro Liver Applications
• In Vivo Liver Function and Structure
• Liver Metabolism
• In Vitro Liver Models
• Co-cultures of Hepatocytes and Macrophages
• 3D Liver Models
• Bioprinted Liver Tissue
• Detected Hepatosphere Structures and Functionality
• Ideal Criteria
• Drug Resistance
• Transporter Studies
• Achieving Heterotypic Cell-Cell Contacts
• Unmet Needs and Future Drivers of Innovation
• Morphogen Signaling
• Multi-donor Liver Cells
• Kidney Toxicity Applications
• Future Challenge: Stem-Cell Derived Kidney Cells
• Bioprinted Kidney Tissue
• Pancreatic Toxicology Applications
• Cardiovascular Toxicity
• Commercial Avenue
• Collaboration with Regulators
• Cardiovascular Drug Discovery
• Microelectrode Arrays (MEAs) Based on Impedance
• Surrogate for Aortic Ring Assay via Bioprinted Magnetics
• Vasodilator Activity
• 3D Engineered Heart Tissues

Chapter 9 Market Breakdown by Region

• Introduction
• North America
• United States
• Canada
• Europe
• Germany
• United Kingdom
• Asia-Pacific
• China
• Japan
• India
• South Korea
• Singapore
• Rest of the World

Chapter 10 Stem Cell Landscape

• A History of Stem Cells
• Major and Minor Research Areas for Stem Cells
• 3D Stem Cell Culture Systems
• Plate or Culture Dish
• Spinner Flask and Rotating Wall Vessel
• Perfusion Bioreactor and Microcarrier Systems
• Shortcomings
• Microfluidics and Stem Cells
• Short Review of Stem Cell Biology
• Embryogenesis
• Growth, Structure and Morphology of Stem Cells
• Stem Cell Differentiation
• Stem Cell Differentiation versus Proliferation
• Extracellular Matrix and Stem Cells
• Soluble Factors
• Manufacturing Stem Cells
• Controlling Embryoid Body Formation
• Forced Aggregation Cultures
• Hanging-Drop Approach
• Applications
• Stem Cell Markers for High-Throughput Screening
• Teratomas and the Teratoma Assay
• Fujifilm (Cellular Dynamics Inc.)
• Stem Cell Research Breakthroughs
• Stem Cells for Neuroscience Discovery and Development
• Example: Alzheimer's Research
• Background: B-Amyloid Cascade Hypothesis
• Human iPSC-Derived Models
• New 3D Model
• Other Advantages of 3D
• Envisioned Applications
• Other 3D Neuro Applications
• Stem Cells for Cardiovascular Discovery
• Stem Cells for the Development of Regenerative Medicine
• Background: Allogenic versus Autologous
• MicroRNAs
• Induced Pluripotent Stem Cells (IPS)

Chapter 11 Regenerative Medicine: Organ Transplants and Skin Substitutes

• Regenerative Medicine
• Need for Organ Transplants
• Applications in Regenerative Medicine
• Investments in Regenerative Medicine
• Skin Substitutes Industry
• Tissue Culture Allograft and Autograft Products
• Tissue Engineering in Regenerative Medicine

Chapter 12 Company Profiles

• 3D BIOPRINTING SOLUTIONS
• 3D BIOTEK LLC
• 4D TECHNOLOGY CORP.
• ABCAM PLC
• AKRON BIOTECH
• AGILENT TECHNOLOGIES INC.
• ALPCO
• AMSBIO
• BECKMAN COULTER INC.
• BIOINSPIRED SOLUTIONS
• BIOTIME INC.
• BIOVISION INC.
• CELL APPLICATIONS INC.
• CELLINK
• CORNING INC.
• CYPROTEX
• CYTIVA
• CYTOO SA
• EMD MILLIPORE / MERCK KGAA
• EMULATE INC.
• ENVISIONTEC INC.
• EPITHELIX
• EUROFINS SAS
• GREINER BIO-ONE INTERNATIONAL GMBH
• HAMILTON ROBOTICS
• HUB ORGANOIDS
• HUREL CORP.
• INSPHERO
• INVITROCUE
• KIYATEC INC.
• LIFENET HEALTH
• LOREM VASCULAR / CYTORI THERAPEUTICS INC.
• MATTEK
• MIMETAS INC.
• ORGANOVO HOLDINGS INC.
• PERKINELMER INC.
• PLASTICELL LTD.
• PLURISTEM THERAPEUTICS INC.
• POIETIS
• PROMEGA CORP.
• SEAHORSE BIOSCIENCE
• STEMCELL TECHNOLOGIES
• STRATATECH CORP.
• SYNVIVO INC.
• TAP BIOSYSTEMS
• TECAN TRADING AG
• ZEN-BIO INC.